Dr. Robert Huizinga reports

KANE BIOTECH RESTARTS COMMERCIAL ACTIVITIES AND STRENGTHENS NORTH AMERICAN MANAGEMENT

Kane Biotech Inc. is resuming commercial activities in both the United States and Canada for its revyve antimicrobial wound gel product line. It has also appointed two seasoned industry leaders to drive business development across North America.

The U.S. Food and Drug Administration 510(k) cleared and Health Canada approved revyve antimicrobial wound gel and revyve antimicrobial wound gel spray.

Commercial restart in the U.S. and Canada

In the U.S., Kane has signed non-exclusive distribution/sales agreements with Medstream Healthcare Solutions, LLC (Dorval, Fla.) and Patient Care Medical (Austin, Tex.) with initial shipments expected in the near term.

In Canada, Kane has resumed commercial activity by converting its distribution agreement with Best Buy Medical Canada to a non-exclusive arrangement, along with targeted sales and sampling initiatives. While sales to date in both countries are not material, they mark a meaningful restart of Kane's commercial engine.

"We are executing on our commitment to reset Kane Biotech using a disciplined market approach," said Dr. Robert Huizinga, interim chief executive officer of Kane Biotech. "We will continue to generate scientific credibility, clinical validation and with that, the commercial infrastructure."

Strategic management appointments

To support this next phase of growth, Kane has appointed two vice-presidents of business development: Sherida (Kay) Watkins Weaver, vice-president of business development, United States. Ms. Watkins Weaver brings over 20 years of experience in wound care commercialization, including leadership roles at Omeza and Relevate Health. She has led market access, reimbursement and adoption strategies across health systems, long-term care and home health markets. Patti Burke-Martin, vice-president of business development, Canada. Ms. Burke-Martin is a national wound care leader with senior roles at EO2 Concepts, Coloplast and ConvaTec. She has a proven record in building high-performing teams and driving adoption of advanced wound care technologies across Canada.

"Kay and Patti bring deep expertise and trusted relationships in their respective markets," added Dr. Huizinga. "Their leadership will be instrumental as we expand our distribution network and support the growing adoption of revyve."

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost.

We seek Safe Harbor.